Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Gets FDA Nod for Human Testing of Ebola Drug

Premium

Tekmira Pharmaceuticals this week announced that it has received clearance from the US Food and Drug Administration to begin human testing of an RNAi-based treatment for Ebola virus infection.

The drug, TKM-Ebola, was added to Tekmira's pipeline last summer after the company reported data showing that a cocktail of modified siRNAs targeting the Zaire Ebola virus L polymerase, viral protein 24, and viral protein 35 could completely protect non-human primates from a lethal dose of the virus when delivered using proprietary lipid nanoparticles (GSN 8/19/2010).

Tekmira, which is developing TKM-Ebola with the support of a $140 million contract from the US government, expects to begin a phase I trial in early 2012.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.